Perrigo Launches betamethason valerate foam 0.12% Commercially


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Perrigo Company (Nasdaq: PRGO) today announced that it has begun commercial shipments ofbetamethasone valerate foam 0.12%, the generic equivalent of Luxiq®Foam, consistent with the date certain launch settlement previously announced.Cobrek Pharmaceuticals, Inc. ("Cobrek"), which was recently acquired byPerrigo, was first to file, making the product eligible for 180 days ofmarketing exclusivity. Perrigo is entitled to receive 100% of the profits fromnet sales of the product due to the Cobrek acquisition.Betamethasone valerate foam 0.12% is indicated for the relief ofcorticosteroid-responsive skin conditions of the scalp (scalp psoriasis).Brand annual sales were approximately $40 million as measured by SymphonyHealth.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA